Skip to main content

Table 4 Multivariable regression analysis of factors affecting outcome for patients treated with immunotherapy (N = 77 with TMB available)

From: MHC-I genotype and tumor mutational burden predict response to immunotherapy

Group OR (95% CI) P value
Rate of SD ≥ 6 month/PR/CR
 Cutaneous SCC versus others 3.96 (0.69–22.64) 0.12
 TMB ≥ 10 mutations/mb versus < 10 4.51 (1.40–14.61) 0.01
 PD-1/L1 monotherapy versus combination 0.15 (0.04–0.58) 0.006
Progression-free survival
 Male versus female 0.94 (0.53–1.68) 0.83
 Caucasian versus others 0.69 (0.33–1.43) 0.32
 NSCLC versus others 1.52 (0.86–2.67) 0.15
 Cutaneous SCC versus others 0.71 (0.22–2.26) 0.56
 TMB ≥ 10 mutations/mb versus others 0.47 (0.26–0.86) 0.01
 PHBR < 0.5 versus ≥ 0.5 0.75 (0.41–1.38) 0.36
Overall survival
 Male versus female 0.64 (0.33–1.26) 0.20
 Caucasian versus others 0.68 (0.27–1.72) 0.42
 TMB ≥ 10 mutations/mb versus < 10 0.48 (0.24–0.970) 0.04
  1. Variables with P value of ≤ 0.1 in univariate (Table 2) were included in the multivariable regression analysis
  2. Abbreviations: CR complete response, HR hazard ratio, NSCLC non-small cell lung cancer, OR odds ratio, PHBR Patient Harmonic-mean Best Rank, PR partial response, SCC squamous cell carcinoma, SD stable disease, TMB tumor mutational burden